Immunetics appoints John Yonkin as CEO

Immunetics Inc., a Boston company focused on technologies for diagnosing and screening for infectious diseases, said Monday that its board of directors has appointed John Yonkin as chief executive.

Yonkin succeeds Dr. Andrew Levin, the company’s founder. Levin will remain president at Immunetics and will continue to lead its research and development group.

Previously, Yonkin served as vice president for strategic projects at Alere Inc., a Waltham medical testing company previously known as Inverness Medical Innovations. While at Alere, he was the lead executive responsible for the integration of Biosite Inc., following its acquisition by Alere in 2007.


In June, Immunetics received Food and Drug Administration clearance for its BacTx test, which aadresses a critical, global infectious risk in transfusion, caused by the estimated 1 in 2,000 platelet units that are contaminated with bacteria.

“I am very excited to be joining the very talented scientific team at Immunetics as the company prepares to bring to market the innovative BacTx rapid test for bacterial contamination of platelets,” Yonkin said in a statement.

Chris Reidy can be reached at